Search
for
Sort by
Research 661–690 of 1000+
- Prostate Cancer Early Detection, Version 2.2015
- Clinical, histopathological and immunological characteristics of exfoliative cutaneous lupus erythematosus in 25 German short‐haired pointers
- Feline acne and results of treatment with mupirocin in an open clinical trial: 25 cases (1994–96)
- Which plant for which skin disease? Part 2: Dermatophytes, chronic venous insufficiency, photoprotection, actinic keratoses, vitiligo, hair loss, cosmetic indications
- Characterization of Clinical Features of Hospitalized Patients Due to the SARS-CoV-2 Infection in the Absence of Comorbidities Regarding the Sex: An Epidemiological Study of the First Year of the Pandemic in Brazil
- New case of trichorinophalangeal syndrome-like phenotype with a de novo t(2;8)(p16.1;q23.3) translocation which does not disrupt the TRPS1 gene
- Profiling steroid and thyroid hormones with hair analysis in a cohort of women aged 25 to 45 years old
- Functional characterization of OR51B5 and OR1G1 in human lung epithelial cells as potential drug targets for non-type 2 lung diseases
- Peter Kynaston Thomas, 28 June 1926–25 January 2008
- MOESM1 of A missense variant in the coil1A domain of the keratin 25 gene is associated with the dominant curly hair coat trait (Crd) in horse
- Referee report. For: Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study [version 1; referees: 2 approved]
- Comparison of high-dose finasteride (5 mg/day) versus low-dose finasteride (2.5 mg/day) in the treatment of hirsutism
- Verification of the Major Metabolic Oxidation Path for the Naphthoyl Group in Chemoattractant Receptor-Homologous Molecule Expressed on Th2 Cells (CRTh2) Antagonist 2-(2-(1-Naphthoyl)-8-fluoro-3,4-dihydro-1<i>H</i>-pyrido[4,3-<i>b</i>]indol-5(2<i>H</i>)-yl)acetic Acid (Setipiprant/ACT-129968)
- Small cell lung cancer: Results of a phase II study of 1,2,4 triglycidylurazol
- Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia
- Efficacy and Safety of Oral Dutasteride 0.5 mg Combined with Oral Minoxidil 2.5 mg for Male Androgenetic Alopecia: A Retrospective Cohort Study
- Referee report. For: Autologous stromal vascular fraction cells combined with platelet-rich plasma for androgenic alopecia treatment: a case series [version 1; peer review: 2 approved with reservations]
- Five year results of a prospective very low calorie diet or conventional weight loss programme in type 2 diabetes
- Menopause, skin and common dermatoses. Part 2: skin disorders
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Lack of evidence of a role for the neurosteroid allopregnanolone in ethanol-induced reward and c-fos expression in DBA/2 mice
- Complications Post-COVID-19 and Risk Factors among Patients after Six Months of a SARS-CoV-2 Infection: A Population-Based Prospective Cohort Study
- Immunofluorescence Tomography: High-resolution 3-D reconstruction by serial-sectioning of methacrylate embedded tissues and alignment of 2-D immunofluorescence images
- Randomized clinical trial of low-dose oral minoxidil for the treatment of female pattern hair loss: 0.25 mg versus 1 mg
- Oral Presentations: Abstracts of the Urological Society of Australia and New Zealand Annual Scientific Meeting, 25–28 February 2023, Melbourne, Australia
- Essential oils-based nanoemulsion formulation boosts hair growth in C57BL/6 mice as compared to minoxidil 2%
- Correction to ‘Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study’
- Dose-Response Relationship of Therapeutic Oxygen: More Is Not Necessarily Better and May Be Inferior to No Supplemental Oxygen – Part 2: Implications and Consequences
- การศึกษาแบบสุ่มและทดสอบความไม่ด้อยกว่า ของ ยาไมนอกซิดิลชนิดรับประทานขนาด 1.25 มิลลิกรัมต่อวัน เปรียบเทียบกับ ยาทา5%ไมนอกซิดิลในการรักษาโรคผมบางจากพันธุกรรมในเพศหญิง
- Posters Presented at the 19th Joint Meeting of the International Society of Dermatopathology, March 2–3, 2016, Hilton Crystal City at Washington Reagan National Airport, Arlington, Virginia, USA